Development of innovative antimicrobials against pathogens resistant to antimicrobials[E8]

公告より

Call: Cluster 1 - Health (Single stage - 2027/1). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities have a better understanding of and access to new and innovative products for the treatment of antimicrobial resistant bacteria and fungi, as well as for further clinical investigation. Candidate therapies are available to treat patients for antimicrobial resistant bacteria and fungi, increasing therapeutic options for clinical deployment in the fight against Antimicrobial Resistance (AMR). Scope: The rapid rise of AMR presents a formidable threat to public health, challenging our ability to treat infections that were once easily managed with standard antimicrobials. As pathogens continually adapt and develop resistance to existing drugs, the efficacy of these treatments diminishes, leading to more severe and prolonged illnesses, increased healthcare costs and productivity losses, and higher mortality rates. This escalating crisis underscores an urgent need for viable therapeutic alternatives required to reduce the burden of diseases caused by antibiotic resistance. Innovative solutions are crucial to maintaining effective disease management and safeguarding public health. Propos…[E3]

公告の詳細は情報源が公開したとおりに表示しています。当社が抽出する事実と要件は英語で記載しています。

• 対象Universities and research. 掲載文の言葉から SLETOR が分類しました。
• 条件EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]

• リスクThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
• 不明We read the funder's listing, not the full guidance or application forms.

1. 入札受付開始 · 2026年10月29日, 07:41 UTC

   The funder published the call with a future closing date.

   変更：status, notice type, published at (元の記録 Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08))

2. 初回取得 · 2026年10月28日, 21:22 UTC

   The funder announced the call. Applications have not opened yet.

   元の記録: Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08)

このページの情報はすべて資金提供者の掲載情報からのものです。各項目に読み取った記録と項目名を示します。

1. E1

   The funder is European Commission.

   出典: Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08)、 項目 /metadata/type/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

2. E2

   Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

   “2027-02-17T00:00:00.000+0000”

   出典: Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08)、 項目 /metadata/deadlineDate/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

3. E3

   The buyer describes the requirement in the notice.

   “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed…”

   出典: Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08)、 項目 /metadata/descriptionByte/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

4. E4

   EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

   “EU call topic”

   出典: Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08)、 項目 /metadata/type/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

5. E5

   This is an EU call for proposals.

   “31094502”

   出典: Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08)、 項目 /metadata/status/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

6. E6

   Applications open on 29 Oct 2026.

   “2026-10-29T00:00:00.000+0000”

   出典: Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08)、 項目 /metadata/startDate/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

7. E7

   The Funding & Tenders Portal gives the status as open for submission.

   出典: Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08)、 項目 /metadata/status/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

8. E8

   The notice is titled "Development of innovative antimicrobials against pathogens resistant to antimicrobials".

   出典: Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08)、 項目 /metadata/title/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

9. E9

   The EU contribution per grant is up to EUR 11,000,000 (from EUR 3,000,000).

   出典: Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08)、 項目 /metadata/budgetOverview/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. データのライセンス： Creative Commons Attribution 4.0 (European Commission) ↗ （新しいタブで開きます）. 公告に含まれる個人の連絡先は保存も表示もしません。